2025
Steroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS)
Richard E, Stephenson J, Desai N, Willey V, Gay A, Scott C, Folkerts K, Pessina E, Singh R, Teng C, Oberprieler N. Steroidal Mineralocorticoid Receptor Antagonist Side Effects and Reasons for Discontinuation: A Patient Survey (RELICS-PS). Pragmatic And Observational Research 2025, 16: 121-127. PMID: 40196209, PMCID: PMC11974567, DOI: 10.2147/por.s489802.Peer-Reviewed Original ResearchSteroidal mineralocorticoid receptor antagonistsSide effectsMineralocorticoid receptor antagonistsHealthcare provider recommendationReceptor antagonistPatient toleranceTreatment patternsPast usersTreatment optionsMale gynecomastiaEligible patientsProvider recommendationPharmacy claimsPatientsResearch DatabaseMedication effectsMedical claimsPatient surveyHealthcare providersChronic conditionsTreatmentPatient perspectiveProvider decision-making processesSafety and feasibility of concomitant scalp cooling and limb cryocompression to prevent paclitaxel-induced alopecia and neuropathy
Bandla A, Wong R, Santhanakrishnan P, Magarajah G, Yee Y, Ng W, Ow S, Chan G, Choo J, Lim S, Wong A, Vijayan J, Paxman R, Lee Y, Hui F, Hairom Z, Ang E, Loprinzi C, Thakor N, Lee S, Kumarakulasinghe N, Lim J, Sundar R. Safety and feasibility of concomitant scalp cooling and limb cryocompression to prevent paclitaxel-induced alopecia and neuropathy. Supportive Care In Cancer 2025, 33: 180. PMID: 39937296, PMCID: PMC11821790, DOI: 10.1007/s00520-024-08982-6.Peer-Reviewed Original ResearchConceptsChemotherapy-induced alopeciaChemotherapy-induced peripheral neuropathyScalp coolingHealthy volunteersCancer patientsPrevention of chemotherapy-induced alopeciaCIPN preventionPrevent chemotherapy-induced peripheral neuropathyEORTC QualityWeekly paclitaxel chemotherapyQOL scoresStandard-of-careBody temperature changesCryocompressionCore body temperature changesWeekly paclitaxelCTCAE v4.0Paclitaxel chemotherapyPhysician gradingLimbPatient toleranceAdverse eventsPeripheral neuropathyChemotherapyCryotherapy
2020
Concomitant limb cryocompression and scalp cooling to reduce paclitaxel-induced neuropathy and alopecia.
Sundar R, Magarajah G, Ow S, Chan G, Choo J, Eng L, Wong A, Vijayan J, Hairom Z, Ang E, Paxman R, Wilder-Smith E, Thakor N, Lee S, Bandla A. Concomitant limb cryocompression and scalp cooling to reduce paclitaxel-induced neuropathy and alopecia. Journal Of Clinical Oncology 2020, 38: e24157-e24157. DOI: 10.1200/jco.2020.38.15_suppl.e24157.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyPaclitaxel-induced neuropathyChemotherapy-induced alopeciaPost-chemotherapyScalp coolingAdverse effects of paclitaxelPreservation of nerve functionWeekly paclitaxel chemotherapyToxicity of paclitaxelEffects of paclitaxelReducing chemotherapy-induced alopeciaBreast cancer patientsLimb hypothermiaProof-of-concept studyPaclitaxel chemotherapyHypothermia trialTransient erythemaNo significant differencePatient toleranceRandomized studyNerve functionPre-chemotherapyPeripheral neuropathyChemotherapyCancer patients
2007
A Phase I Pilot Study of Autologous Heat Shock Protein Vaccine HSPPC-96 in Patients With Resected Pancreatic Adenocarcinoma
Maki R, Livingston P, Lewis J, Janetzki S, Klimstra D, DeSantis D, Srivastava P, Brennan M. A Phase I Pilot Study of Autologous Heat Shock Protein Vaccine HSPPC-96 in Patients With Resected Pancreatic Adenocarcinoma. Digestive Diseases And Sciences 2007, 52: 1964-1972. PMID: 17420942, DOI: 10.1007/s10620-006-9205-2.Peer-Reviewed Original ResearchConceptsPhase I pilot studyHSPPC-96Pancreatic adenocarcinomaImmune responseHSPPC-96 vaccinationMedian overall survivalResectable pancreas adenocarcinomaResectable pancreatic adenocarcinomaDose-limiting toxicityMultiple dose levelsTolerability of vaccinationYear Follow-UpCourse of vaccinationKaplan-Meier estimatesAntitumor reactivityOverall survivalAdjuvant chemotherapyELISPOT assayTumor specimensT cellsPatient toleranceClinical outcomesPancreas adenocarcinomaTreated patientsFollow-up
1998
Steady-state and dynamic MR angiography with MS-325: initial experience in humans.
Grist T, Korosec F, Peters D, Witte S, Walovitch R, Dolan R, Bridson W, Yucel E, Mistretta C. Steady-state and dynamic MR angiography with MS-325: initial experience in humans. Radiology 1998, 207: 539-44. PMID: 9577507, DOI: 10.1148/radiology.207.2.9577507.Peer-Reviewed Original ResearchConceptsDynamic MR angiographyMR angiographyPhase I clinical trialSelective arterial enhancementPostcontrast imagesSteady state imagesMS-325Long blood residence timeMagnetic resonance angiographyLate postcontrast imagesBlood pool contrast agentPatient toleranceClinical trialsArterial enhancementHealthy volunteersIntravenous injectionResonance angiographyInitial experienceCarotid vesselsAngiographyVascular signalsBlood residence timeLate imagesMR angiogramsVolunteers
1972
Clinical study with bleomycin: Tolerance to twice weekly dosage
Ohnuma T, Selawry O, Holland J, DeVita V, Shedd D, Hansen H, Muggia F. Clinical study with bleomycin: Tolerance to twice weekly dosage. Cancer 1972, 30: 914-922. PMID: 4116909, DOI: 10.1002/1097-0142(197210)30:4<914::aid-cncr2820300409>3.0.co;2-8.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaCell carcinomaDose levelsObjective tumor responseBody surface areaTherapeutic dose levelsOptimal dose levelNew antineoplastic agentsPulmonary infiltratesTransient hypertensionUrinary burningAbdominal distentionComplete remissionHematologic toxicityCutaneous toxicityWeekly dosesProlonged courseAdditional patientsPatient toleranceSkin toxicityMalignant neoplasmsTesticular carcinomaTumor responseTumor regressionWeekly dosage
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply